Filing Details
- Accession Number:
- 0001384101-19-000140
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-27 16:28:37
- Reporting Period:
- 2019-11-25
- Accepted Time:
- 2019-11-27 16:28:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1384101 | Veracyte Inc. | VCYT | Services-Medical Laboratories (8071) | 205455398 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1543503 | Keith Kennedy | 6000 Shoreline Court, Suite 300 South San Francisco CA 94080 | Coo / Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-11-25 | 18,757 | $5.98 | 128,800 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-11-25 | 18,757 | $28.01 | 110,043 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2019-11-25 | 18,757 | $0.00 | 18,757 | $5.98 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
57,250 | 2028-03-01 | No | 4 | M | Direct |
Footnotes
- The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019.
- Represents weighted average sales price. Sale prices for the transactions range from $28.00 to $28.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.